Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$0.27
-3.3%
$0.37
$0.17
$2.04
$39.13M0.992.43 million shs318,532 shs
Celcuity, Inc. stock logo
CELC
Celcuity
$11.76
-3.2%
$11.16
$7.58
$19.77
$445.16M0.37282,786 shs26,378 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.33
$0.25
$1.20
$17.03M1.19170,772 shs4.12 million shs
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$10.75
-0.3%
$10.76
$10.20
$11.30
$156.52M-0.01121,140 shs3,300 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
+1.93%-3.27%-19.67%-63.40%-83.32%
Celcuity, Inc. stock logo
CELC
Celcuity
+6.11%+3.14%+16.38%+16.38%-27.07%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-27.13%-70.18%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biodesix, Inc. stock logo
BDSX
Biodesix
2.7592 of 5 stars
4.42.00.00.00.02.50.6
Celcuity, Inc. stock logo
CELC
Celcuity
1.184 of 5 stars
3.60.00.00.00.02.50.0
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.80
Moderate Buy$1.75557.89% Upside
Celcuity, Inc. stock logo
CELC
Celcuity
3.17
Buy$30.80161.90% Upside
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CELC, HHLA, BDSX, and ENZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.00
5/19/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/15/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.50 ➝ $1.50
5/14/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
4/29/2025
Biodesix, Inc. stock logo
BDSX
Biodesix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.50 ➝ $2.50
4/11/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
4/1/2025
Celcuity, Inc. stock logo
CELC
Celcuity
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$71.32M0.55N/AN/A$0.14 per share1.90
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$3.11 per shareN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/A$1.71 per share6.29($1.19) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$42.93M-$0.29N/AN/AN/A-54.28%-167.28%-39.96%8/6/2025 (Estimated)
Celcuity, Inc. stock logo
CELC
Celcuity
-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$17.69M-$0.14N/AN/AN/A-57.47%-0.35%N/A

Latest CELC, HHLA, BDSX, and ENZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.95-$0.86+$0.09-$0.86N/AN/A
5/13/2025Q1 2025
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million
3/31/2025Q4 2024
Celcuity, Inc. stock logo
CELC
Celcuity
-$0.72-$0.85-$0.13-$0.85N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
3.32
2.22
2.22
Celcuity, Inc. stock logo
CELC
Celcuity
1.14
6.61
6.61
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A
0.03
0.03

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
39.24%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
30.10%
Celcuity, Inc. stock logo
CELC
Celcuity
15.78%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
220146.56 million102.45 millionOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
4037.87 million31.89 millionOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A14.56 million14.48 millionNot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$0.27 -0.01 (-3.34%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Celcuity stock logo

Celcuity NASDAQ:CELC

$11.76 -0.39 (-3.21%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

HH&L Acquisition stock logo

HH&L Acquisition NYSE:HHLA

HH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.